par Wald, Noémie 
;Le Corre, Yannick;Martin, L;Mathieu, Véronique ;Goormaghtigh, Erik
Référence Biochimica et biophysica acta. Molecular basis of disease, 1862, 2, page (174-181)
Publication Publié, 2016-02
;Le Corre, Yannick;Martin, L;Mathieu, Véronique ;Goormaghtigh, Erik Référence Biochimica et biophysica acta. Molecular basis of disease, 1862, 2, page (174-181)
Publication Publié, 2016-02
Article révisé par les pairs
| Résumé : | Metastatic melanomas are highly aggressive and median survival is 6-9. months for stage IV patients in the absence of treatment with anti-tumor activity. Dacarbazine is an alkylating agent that has been widely used in the treatment of metastatic melanomas and that could be still used in combination with targeted or immune therapies. Indeed, therapeutic benefits of these treatments in monotherapy are poor and one option to improve them is to combine drugs and/or to better anticipate the individual response to a defined treatment. To our best knowledge and to date, there is no test available to predict the response of a patient to dacarbazine. We show here that examination of melanoma histological sections by infrared micro-spectroscopy reveals the sensitivity of the cancer to dacarbazine. Unsupervised analysis of the FTIR spectra evidences spontaneous and significant clustering of infrared spectra into two groups that match the clinical responsiveness of the patients to dacarbazine used as a first-line treatment. A supervised model resulted in 83% of the patient status (responder/non-responder) being correctly identified. The spectra revealed a key modification in the nature and quantity of lipids in the cells of both groups. |
